Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HAVCR2 | Q8TDQ0 | 1/20 | 0.42 |
| ▸ | PRKAG1 | P54619 | 2/20 | 0.39 |
| ▸ | PRKAA1 | Q13131 | 2/20 | 0.39 |
| ▸ | PRKAB1 | Q9Y478 | 2/20 | 0.39 |
| ▸ | ACLY | P53396 | 2/20 | 0.38 |
| ▸ | CTSA | P10619 | 2/20 | 0.37 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.36 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.36 |
| ▸ | PRKAG3 | Q9UGI9 | 1/20 | 0.36 |
| ▸ | PRKAG2 | Q9UGJ0 | 1/20 | 0.36 |
| ▸ | RXRA | P19793 | 1/20 | 0.36 |
| ▸ | RXRB | P28702 | 1/20 | 0.36 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.35 |
| ▸ | CNR2 | P34972 | 2/20 | 0.35 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | DHODH | Q02127 | 1/20 | 0.34 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29440739 | 1.00 | HAVCR2 (0.42) | HAVCR2PRKAG1PRKAA1PRKAB1ACLY | |
| Hydrochloric Acid SCHEMBL30853500 | 0.99 | HAVCR2 (0.41) | HAVCR2PRKAG1PRKAA1PRKAB1ACLY | |
| Hydrochloric Acid SCHEMBL28436307 | 0.99 | HAVCR2 (0.41) | HAVCR2PRKAG1PRKAA1PRKAB1ACLY | |
| SCHEMBL21101258 | 0.92 | CTSA (0.37) | HAVCR2PRKAG1PRKAA1PRKAB1CTSA | |
| SCHEMBL22118244 | 0.86 | ATF1 (0.38) | CTSAGPBAR1CNR2NUDT1CYP3A4 | |
| SCHEMBL21101402 | 0.86 | KMT2A (0.44) | HAVCR2CYP3A4CYP2C8CYP2C9DHODH | |
| SCHEMBL29643212 | 0.85 | GPBAR1 (0.41) | HAVCR2ACLYCTSARXRARXRB | |
| SCHEMBL20702326 | 0.85 | MEN1 (0.47) | — | |
| SCHEMBL20139032 | 0.84 | HAVCR2 (0.47) | HAVCR2RXRARXRBCNR2CYP3A4 | |
| SCHEMBL30071148 | 0.84 | HAVCR2 (0.47) | HAVCR2RXRARXRBCNR2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12448391-B2 | Bicyclic derivatives for treating endoparasites | ELANCO TIERGESUNDHEIT AG (CH) | 2025-10-21 | — | — | US | disclosed |
| US-20240360116-A1 | BICYCLIC DERIVATIVES | ELANCO TIERGESUNDHEIT AG (SZ) | 2024-10-31 | — | — | US | disclosed |
| CN-116888124-A | Bicyclic derivatives | 礼蓝动物保健有限公司 | 2023-10-13 | — | — | CN | disclosed |
| US-20220242857-A1 | BICYCLIC DERIVATIVES FOR TREATING ENDOPARASITES | ELANCO TIERGESUNDHEIT AG (CH) | 2022-08-04 | — | — | US | disclosed |
| CN-114206860-A | Bicyclic derivatives for the treatment of endoparasites | 礼蓝动物保健有限公司 | 2022-03-18 | — | — | CN | disclosed |
| US-20200385398-A1 | NEW BICYCLIC DERIVATIVES | ELANCO TIERGESUNDHEIT AG | 2020-12-10 | — | — | US | disclosed |
| WO-2020247747-A1 | BICYCLIC DERIVATIVES FOR TREATING ENDOPARASITES | ELANCO TIERGESUNDHEIT AG (CH) | 2020-12-10 | — | — | WO | disclosed |
| US-20200308153-A1 | PROCESS FOR PREPARING ANTIHELMINTIC 4-AMINO-QUINOLINE-3-CARBOXAMIDE DERIVATIVES | BAYER ANIMAL HEALTH GMBH (DE) | 2020-10-01 | — | — | US | disclosed |
| CN-111448192-A | Process for preparing anthelmintic 4-amino-quinoline-3-carboxamide derivatives | 拜耳动物保健有限责任公司 | 2020-07-24 | — | — | CN | disclosed |
| WO-2019115768-A1 | PROCESS FOR PREPARING ANTIHELMINTIC 4-AMINO-QUINOLINE-3-CARBOXAMIDE DERIVATIVES | BAYER ANIMAL HEALTH GMBH (DE) | 2019-06-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12448391-B2 | Bicyclic derivatives for treating endoparasites | TBXA2R, PIGS, CYCS | HAVCR2 3986/4885PRKAG1 4083/4885PRKAA1 2990/4885 |
| US-20240360116-A1 | BICYCLIC DERIVATIVES | FABP3, CYCS, TNNI3 | HAVCR2 3319/4885PRKAG1 4667/4885PRKAA1 4038/4885 |
| US-20220242857-A1 | BICYCLIC DERIVATIVES FOR TREATING ENDOPARASITES | TBXA2R, PIGS, CYCS | HAVCR2 3986/4885PRKAG1 4083/4885PRKAA1 2990/4885 |
| US-20200385398-A1 | NEW BICYCLIC DERIVATIVES | CYCS, FABP3, TNNI3 | HAVCR2 3886/4885PRKAG1 4597/4885PRKAA1 3876/4885 |
| US-20200308153-A1 | PROCESS FOR PREPARING ANTIHELMINTIC 4-AMINO-QUINOLINE-3-CARBOXAMIDE DERIVATIVES | HRH4, HRH2, HRH1 | HAVCR2 3900/4885PRKAG1 3411/4885PRKAA1 3199/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.